NikoleV Posted February 1 Share Posted February 1 While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, driver mutations are key to driving the development of cancer. There are many driver mutations. Researchers have been developing drugs that target specific driver mutations in lung cancer, creating therapies for those patients whose lung cancer harbors them. Read our latest blog where Dr. John Heymach, MD Anderson Cancer Center and member of LUNGevity’s Scientific Advisory Board, dissucses making personalized medicine even more personal. https://www.lungevity.org/blogs/researchers-make-new-inroads-for-egfr-exon20-nsclc-patients Judy M2 1 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.